New combo aims to revive immune attack on hard-to-treat cervical cancer
NCT ID NCT06157151
First seen Nov 14, 2025 · Last updated May 15, 2026 · Updated 23 times
Summary
This study tests a new drug, PRGN-2009, combined with pembrolizumab in 24 adults whose recurrent or metastatic cervical cancer no longer responds to pembrolizumab alone. The goal is to see if the combination can shrink tumors or stop them from growing. Participants must have HPV-positive cancer and be in good overall health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institute of Health
RECRUITINGBethesda, Maryland, 20892, United States
Contact Email: •••••@•••••
-
University of Arkansas for Medical Sciences
RECRUITINGLittle Rock, Arkansas, 72205, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Washington
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.